Richard A. Helmers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Richard A. Helmers has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Adela Grando
Arizona State University, Tempe, AZ
1 shared publicationAngela M. Eberhardt
Operations Administrator, Mayo Clinic Health System
1 shared publication- Bhavesh Patel
Department of Critical Care Medicine, Mayo Clinic College of Medicine, Mayo Clinic Hospital, Mayo Clinic, Phoenix, Arizona, USA
1 shared publication Bradley N. Doebbeling
Arizona State University, Tempe, AZ
1 shared publicationBradly J. Narr
Department of Anesthesiology, Mayo Clinic, Rochester, MN
1 shared publicationC. Michel Harper
Mayo Clinic College of Medicine, Rochester, MN, United States; Mayo Clinic College of Medicine, United States
1 shared publication
Latest Publications
- Open Access
- 1 August 2021
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 5 (4) , 693-699
Regional Specialty Surgical Practice Efficiencies Gained as a Result of COVID-19
- 1 August 2021
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 5 (4) , 693-699
Open AccessRegional Specialty Surgical Practice Efficiencies Gained as a Result of COVID-19
- Open Access
- 1 September 2019
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 3 (3) , 319-326
Mayo Clinic Registry of Operational Tasks (ROOT)
- 1 September 2019
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 3 (3) , 319-326
Open AccessMayo Clinic Registry of Operational Tasks (ROOT)
- 1 September 2019
- Published by Elsevier in Healthcare
- Vol. 7 (3) , 100330
The mayo clinic model of clinical integration
- 1 September 2019
- Published by Elsevier in Healthcare
- Vol. 7 (3) , 100330
The mayo clinic model of clinical integration
- Open Access
- 1 January 2018
- Published by Medknow in Journal of Anaesthesiology Clinical Pharmacology
- Vol. 34 (2) , 260-261
Refractory ICP with Mycotic Aneurysm – 23.4% Saline or Mannitol?
- 1 January 2018
- Published by Medknow in Journal of Anaesthesiology Clinical Pharmacology
- Vol. 34 (2) , 260-261
Open AccessRefractory ICP with Mycotic Aneurysm – 23.4% Saline or Mannitol?
- Open Access
- 1 December 2017
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 1 (3) , 234-241
Overall Cost Comparison of Gastrointestinal Endoscopic Procedures With Endoscopist- or Anesthesia-Supported Sedation by Activity-Based Costing Techniques
- 1 December 2017
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 1 (3) , 234-241
Open AccessOverall Cost Comparison of Gastrointestinal Endoscopic Procedures With Endoscopist- or Anesthesia-Supported Sedation by Activity-Based Costing Techniques
- 1 September 2015
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 90 (9) , 1294-1297
Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient
- 1 September 2015
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 90 (9) , 1294-1297
Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient
- 1 March 2014
- Published by Elsevier in Heart & Lung
- Vol. 43 (2) , 155-157
Nitric oxide therapy for post-laparoscopic surgery associated patent foramen ovale: Incidence, mechanisms, diagnosis and therapy
- 1 March 2014
- Published by Elsevier in Heart & Lung
- Vol. 43 (2) , 155-157
Nitric oxide therapy for post-laparoscopic surgery associated patent foramen ovale: Incidence, mechanisms, diagnosis and therapy
- Open Access
- 17 July 2006
- Published by Springer Nature in Critical Care
- Vol. 10 (4) , R101
Corticosteroids influence the mortality and morbidity of acute critical illness
Introduction: Use of corticosteroids for adrenal supplementation and attenuation of the inflammatory and immune response is widespread in acute critical illness. The study hypothesis was that exposure to corticosteroids influences the mortality and morbidity in acute critical illness. Methods: This case–control retrospective study was performed in a single multidisciplinary intensive care unit at a tertiary care institution and consisted of 10,285 critically ill patients admitted between 1 January 1999 and 31 December 2004. Demographics, comorbidities, acute illness characteristics including severity measured by Sequential Organ Failure Assessment, concurrent medications, therapeutic interventions and incidence of infections were obtained from electronic medical records, were examined with multiple regression analysis and were adjusted for propensity of corticosteroid exposure. The primary outcome was hospital death, and the secondary outcome was transfer to a care facility at hospital discharge. Results: Corticosteroid exposure in 2,632 (26%) patients was characterized by younger age, more females, higher Charlson comorbidity and maximal daily Sequential Organ Failure Assessment scores compared with control patients. Corticosteroids potentiated metabolic and neuromuscular sequels of critical illness with increased requirements for diuretics, insulin, protracted weaning from mechanical ventilation, need for tracheostomy and discharge to a care facility. Early exposure to corticosteroids predisposed to recurrent and late onset of polymicrobial and fungal hospital-acquired infections. Corticosteroids increased the risk for death or disability after adjustments for comorbidities and acute illness characteristics. Conclusion: Corticosteroids increased the risk for death or disability in critical illness. Hospital-acquired infections and metabolic and neuromuscular sequels of critical illness were exacerbated by corticosteroids. Careful appraisal of the indications for use of corticosteroids is necessary to balance the benefits and risks from exposure in acute critical illness.
- 17 July 2006
- Published by Springer Nature in Critical Care
- Vol. 10 (4) , R101
Open AccessCorticosteroids influence the mortality and morbidity of acute critical illness
Introduction: Use of corticosteroids for adrenal supplementation and attenuation of the inflammatory and immune response is widespread in acute critical illness. The study hypothesis was that exposure to corticosteroids influences the mortality and morbidity in acute critical illness. Methods: This case–control retrospective study was performed in a single multidisciplinary intensive care unit at a tertiary care institution and consisted of 10,285 critically ill patients admitted between 1 January 1999 and 31 December 2004. Demographics, comorbidities, acute illness characteristics including severity measured by Sequential Organ Failure Assessment, concurrent medications, therapeutic interventions and incidence of infections were obtained from electronic medical records, were examined with multiple regression analysis and were adjusted for propensity of corticosteroid exposure. The primary outcome was hospital death, and the secondary outcome was transfer to a care facility at hospital discharge. Results: Corticosteroid exposure in 2,632 (26%) patients was characterized by younger age, more females, higher Charlson comorbidity and maximal daily Sequential Organ Failure Assessment scores compared with control patients. Corticosteroids potentiated metabolic and neuromuscular sequels of critical illness with increased requirements for diuretics, insulin, protracted weaning from mechanical ventilation, need for tracheostomy and discharge to a care facility. Early exposure to corticosteroids predisposed to recurrent and late onset of polymicrobial and fungal hospital-acquired infections. Corticosteroids increased the risk for death or disability after adjustments for comorbidities and acute illness characteristics. Conclusion: Corticosteroids increased the risk for death or disability in critical illness. Hospital-acquired infections and metabolic and neuromuscular sequels of critical illness were exacerbated by corticosteroids. Careful appraisal of the indications for use of corticosteroids is necessary to balance the benefits and risks from exposure in acute critical illness.